Resources & Guides

Retatrutide is not FDA-approved. Lilly is reported to plan an FDA filing in early 2027, and a decision in late 2027 or 2028 is our estimate, not Lilly's. Here's everything you need to know about its regulatory status, trial progress, and how to access it today.

Tirzepatide is FDA-approved under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Compounded tirzepatide is a different story. Here is the full approval timeline, brand-by-brand indications, eligibility, and the compounded vs brand distinction.

Retatrutide is not commercially available. Phase 3 results have been reported and Lilly plans an FDA filing in early 2027, with a decision possible in late 2027 or 2028 (our estimate, not Lilly's). In the US, lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). Compounding pharmacies cannot lawfully supply it. Here is everything you need to know about retatrutide availability worldwide.

Both Ozempic and Wegovy contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes (max 1.0 mg) while Wegovy targets obesity (2.4 mg recommended maintenance, 7.2 mg maximum). Explore the differences.